rs1440280370
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PVS1_StrongPS4_ModeratePP1_ModeratePM5_SupportingPM2_Supporting
This summary comes from the ClinGen Evidence Repository: The c.48+1G>A is a canonical splice variant predicted to result in a truncated or absent protein (PVS1_Strong, PM5_Supporting). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least two families meeting HDGC clinical criteria (PS4_Moderate; PMID:20719348, 24366306). The variant was also found to co-segregate with disease in multiple affected family members, with 5 or 6 meioses observed (PP1_Moderate; SCV000617359.1). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Strong, PM2_Supporting, PS4_Moderate and PP1_Moderate, PM5_Supporting. LINK:https://erepo.genome.network/evrepo/ui/classification/CA396451431/MONDO:0007648/007
Frequency
Consequence
NM_004360.5 splice_donor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CDH1 | NM_004360.5 | c.48+1G>A | splice_donor_variant | ENST00000261769.10 | |||
CDH1 | NM_001317184.2 | c.48+1G>A | splice_donor_variant | ||||
CDH1 | NM_001317185.2 | c.-1568+1G>A | splice_donor_variant | ||||
CDH1 | NM_001317186.2 | c.-1772+1G>A | splice_donor_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CDH1 | ENST00000261769.10 | c.48+1G>A | splice_donor_variant | 1 | NM_004360.5 | P1 | |||
CDH1 | ENST00000422392.6 | c.48+1G>A | splice_donor_variant | 1 | |||||
CDH1 | ENST00000566612.5 | c.48+1G>A | splice_donor_variant, NMD_transcript_variant | 1 | |||||
CDH1 | ENST00000566510.5 | c.48+1G>A | splice_donor_variant, NMD_transcript_variant | 5 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1385264Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 684244
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hereditary diffuse gastric adenocarcinoma Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | European Reference Network on Genetic Tumour Risk Syndromes (ERN-GENTURIS), i3s - Instituto de InvestigaĆ§Ć£o e InovaĆ§Ć£o em SaĆŗde, University of Porto | Aug 01, 2022 | PVS1_Strong; PS4_Moderate; PM2; PP1_Moderate (PMID: 30311375) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Jun 08, 2023 | This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. - |
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | Jul 02, 2018 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jul 20, 2017 | This variant is denoted CDH1 c.48+1G>A or IVS1+1G>A and consists of a G>A nucleotide substitutionat the +1 position of intron 1 of the CDH1 gene. This variant destroys a canonical splice donor site and is predicted tocause abnormal gene splicing, leading to either an abnormal message that is subject to nonsense-mediated mRNAdecay or to an abnormal protein product. CDH1 c.48+1G>A has been reported in at least two families; one presentingwith multiple cases of diffuse gastric cancer while the other is reported to only have lobular breast cancer (Pandalai2011, Petridis 2014). Based on the current evidence, we consider this variant to be pathogenic - |
CDH1-related diffuse gastric and lobular breast cancer syndrome Pathogenic:1
Pathogenic, reviewed by expert panel | curation | ClinGen CDH1 Variant Curation Expert Panel | Aug 29, 2023 | The c.48+1G>A is a canonical splice variant predicted to result in a truncated or absent protein (PVS1_Strong, PM5_Supporting). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least two families meeting HDGC clinical criteria (PS4_Moderate; PMID: 20719348, 24366306). The variant was also found to co-segregate with disease in multiple affected family members, with 5 or 6 meioses observed (PP1_Moderate; SCV000617359.1). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Strong, PM2_Supporting, PS4_Moderate and PP1_Moderate, PM5_Supporting. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 01, 2022 | The c.48+1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide after coding exon 1 of the CDH1 gene. This alteration has been reported in a family affected with gastric cancers, colon cancer, and signet cell carcinoma of the cecum. Three unaffected members of this family were found to carry the c.48+1G>A pathogenic mutation and elected prophylactic gastrectomies. Post-surgical evaluations of all three gastrectomy specimens showed multiple foci of intramucosal adenocarcinoma and/or of signet ring cell carcinoma in situ (Pandalai PK et al. Surgery. 2011 Mar;149(3):347-55; Fujita H et al. Am J Surg Pathol. 2012 Nov;36(11):1709-17). This mutation has also been reported in one individual with a family history of breast cancer and a personal history of bilateral lobular breast cancer in situ (LCIS) and bilateral invasive lobular breast cancer (ILC) diagnosed at age 51 (Petridis C et al. Br J Cancer. 2014 Feb 18;110(4):1053-7). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at